NCT01266785View on ClinicalTrials.gov

Infliximab, Regulatory T Cells, IL2 and Crohn's Disease

NAWithdrawnINTERVENTIONAL
0
Timeline

Start Date

December 31, 2010

Primary Completion Date

July 31, 2012

Study Completion Date

July 31, 2012

Conditions
Crohn's Disease
Interventions
DRUG

Infliximab

Patient will receive Infliximab infusions during Weeks 0, 2 and 6. Therefore, the duration of the Infliximab treatment will last 6 weeks.

Trial Locations (1)

97239

Oregon Health & Science University, Portland

Sponsors

Collaborators (1)

Centocor, Inc.
All Listed Sponsors
collaborator

Centocor, Inc.

INDUSTRY

lead

Oregon Health and Science University

OTHER